PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04092595
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
- Conditions
- Stasis Dermatitis
- Interventions
- Drug: crisaborole ointmentOther: vehicle ointment
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04091087
- Locations
- 🇺🇸
Hawthorne Effect, Inc, Lafayette, California, United States
🇺🇸Lightship, El Segundo, California, United States
🇺🇸Onco360 Oncology Pharmacy, Louisville, Kentucky, United States
A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04090047
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
- Conditions
- Hepatic ImpairmentHealthy Volunteers
- Interventions
- Drug: PF-06865571 100 mg
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT04091061
- Locations
- 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 198
- Registration Number
- NCT04079920
- Locations
- 🇬🇷
Nearchou 18, Crete, Greece
🇬🇷251 Air Force Hospital of Athens, Athens, Greece
🇬🇷University General Hospital of Athens "Attikon", Athens, Attiki, Greece
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1769
- Registration Number
- NCT04076787
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
- Conditions
- Respiratory Tract Infection
- Interventions
- Biological: RSV VaccineBiological: TdapBiological: Placebo
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 713
- Registration Number
- NCT04071158
- Locations
- 🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Sundance Clinical Research, Saint Louis, Missouri, United States
🇺🇸East-West Medical Research Institute, Honolulu, Hawaii, United States
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT04071405
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: P3-FastDrug: Comm-FastDrug: Vari-FastDrug: Comm-Fed
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT04065633
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Pharmacokinetics and Safety of RV521 Formulations
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: RV521
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT04065698
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom